Élisa Gobbini

880 total citations
23 papers, 291 citations indexed

About

Élisa Gobbini is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Élisa Gobbini has authored 23 papers receiving a total of 291 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 5 papers in Immunology. Recurrent topics in Élisa Gobbini's work include Lung Cancer Treatments and Mutations (11 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Lung Cancer Research Studies (6 papers). Élisa Gobbini is often cited by papers focused on Lung Cancer Treatments and Mutations (11 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Lung Cancer Research Studies (6 papers). Élisa Gobbini collaborates with scholars based in France, Italy and Germany. Élisa Gobbini's co-authors include Matteo Giaj Levra, Margaux Hubert, Jenny Valladeau‐Guilemond, Christophe Caux, Nathalie Bendriss‐Vermare, Denis Moro‐Sibilot, Dalil Hannani, Anne‐Claire Toffart, Anne‐Claire Doffin and Olivier Trédan and has published in prestigious journals such as Nature Communications, Annals of Oncology and European Journal of Immunology.

In The Last Decade

Élisa Gobbini

18 papers receiving 285 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Élisa Gobbini France 9 169 152 86 73 48 23 291
Mazen Nasrallah United States 7 170 1.0× 140 0.9× 41 0.5× 47 0.6× 36 0.8× 14 290
Lea Lowenfeld United States 9 251 1.5× 214 1.4× 55 0.6× 72 1.0× 29 0.6× 19 362
Jason Cham United States 8 272 1.6× 173 1.1× 84 1.0× 61 0.8× 32 0.7× 20 355
Laura Boullerot France 9 143 0.8× 162 1.1× 32 0.4× 80 1.1× 15 0.3× 17 260
Jichang Han China 6 167 1.0× 178 1.2× 37 0.4× 60 0.8× 24 0.5× 13 299
Rony Kapoor Australia 8 198 1.2× 66 0.4× 52 0.6× 53 0.7× 20 0.4× 15 237
Carlos Linn United States 6 198 1.2× 96 0.6× 87 1.0× 34 0.5× 22 0.5× 15 283
Francesco Sgambelluri Italy 6 73 0.4× 94 0.6× 71 0.8× 78 1.1× 43 0.9× 7 223
Gareth Rivalland Australia 10 112 0.7× 69 0.5× 98 1.1× 78 1.1× 21 0.4× 26 248
Sandra Vogt United States 3 173 1.0× 172 1.1× 27 0.3× 114 1.6× 32 0.7× 3 292

Countries citing papers authored by Élisa Gobbini

Since Specialization
Citations

This map shows the geographic impact of Élisa Gobbini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Élisa Gobbini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Élisa Gobbini more than expected).

Fields of papers citing papers by Élisa Gobbini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Élisa Gobbini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Élisa Gobbini. The network helps show where Élisa Gobbini may publish in the future.

Co-authorship network of co-authors of Élisa Gobbini

This figure shows the co-authorship network connecting the top 25 collaborators of Élisa Gobbini. A scholar is included among the top collaborators of Élisa Gobbini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Élisa Gobbini. Élisa Gobbini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gobbini, Élisa, et al.. (2025). Dendritic cells: the central partner for cancer immunity. OncoImmunology. 14(1). 2571773–2571773.
2.
Gobbini, Élisa, Mamadou Diallo, Dominique Pasquier, et al.. (2025). Clinical characteristics and management of long survivors in extensive stage small cell lung cancer. Lung Cancer. 202. 108499–108499.
3.
Gobbini, Élisa, Alexandra Langlais, Pascale Missy, et al.. (2025). Morphine and metformin impact immunotherapy benefit in patients with NSCLC: Results of the real-world study IFCT-1502 CLINIVO-SNDS. European Journal of Cancer. 225. 115560–115560.
4.
Rodriguez, Céline, Maude Ardin, Anne‐Claire Doffin, et al.. (2025). Type III interferon primes pDCs for TLR7 activation and antagonizes immune suppression mediated by TGF-β and PGE2. Nature Communications. 16(1). 3045–3045. 5 indexed citations
5.
6.
Huet, C., Clémence Basse, Pieter Bonte, et al.. (2024). Outcomes Analysis of Patients Receiving Local Ablative Therapy for Oligoprogressive Metastatic NSCLC Under First-Line Immunotherapy. Clinical Lung Cancer. 25(8). e402–e410.e3. 1 indexed citations
7.
Bayerl, Felix, David Alejandro Bejarano, Anne‐Claire Doffin, et al.. (2023). Guidelines for visualization and analysis of DC in tissues using multiparameter fluorescence microscopy imaging methods. European Journal of Immunology. 53(11). e2249923–e2249923. 14 indexed citations
8.
Hannani, Dalil, et al.. (2022). Immune Checkpoint Inhibitor Rechallenge and Resumption: a Systematic Review. Current Oncology Reports. 24(9). 1095–1106. 23 indexed citations
9.
Giaj‐Levra, Niccolò, et al.. (2022). Immunotherapy in NSCLC Patients With Brain and Leptomeningeal Metastases. Frontiers in Oncology. 12. 787080–787080. 4 indexed citations
10.
Toffart, Anne‐Claire, et al.. (2021). Quels malades peuvent et doivent aller en réanimation ?. Revue des Maladies Respiratoires Actualités. 13(2). 2S244–2S251.
11.
Hubert, Margaux, Élisa Gobbini, Coline Couillault, et al.. (2020). IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. Science Immunology. 5(46). 105 indexed citations
12.
Toffart, Anne‐Claire, et al.. (2020). Advances and Therapeutic Perspectives in Extended-Stage Small-Cell Lung Cancer. Cancers. 12(11). 3224–3224. 5 indexed citations
13.
Gobbini, Élisa, Aurélie Swalduz, Matteo Giaj Levra, et al.. (2020). Implementing ctDNA Analysis in the Clinic: Challenges and Opportunities in Non-Small Cell Lung Cancer. Cancers. 12(11). 3112–3112. 26 indexed citations
14.
Gobbini, Élisa, J. Charles, Anne‐Claire Toffart, et al.. (2020). Literature meta-analysis about the efficacy of re-challenge with PD-1 and PD-L1 inhibitors in cancer patients. Bulletin du Cancer. 107(11). 1098–1107. 9 indexed citations
15.
Gobbini, Élisa, et al.. (2019). Current opinions in immune checkpoint inhibitors rechallenge in solid cancers. Critical Reviews in Oncology/Hematology. 144. 102816–102816. 22 indexed citations
16.
Hubert, Margaux, Élisa Gobbini, Nathalie Bendriss‐Vermare, Christophe Caux, & Jenny Valladeau‐Guilemond. (2019). Human Tumor-Infiltrating Dendritic Cells: From In Situ Visualization to High-Dimensional Analyses. Cancers. 11(8). 1082–1082. 33 indexed citations
17.
18.
Gobbini, Élisa, Sara Pilotto, Giulia Pasello, et al.. (2017). Effect of Contract Research Organization Bureaucracy in Clinical Trial Management: A Model From Lung Cancer. Clinical Lung Cancer. 19(2). 191–198. 4 indexed citations
19.
Salvia, Anna La, Antônio Rossi, Domenico Galetta, et al.. (2016). Intercalated Chemotherapy and Epidermal Growth Factor Receptor Inhibitors for Patients With Advanced Non–Small-cell Lung Cancer: A Systematic Review and Meta-analysis. Clinical Lung Cancer. 18(1). 23–33.e1. 12 indexed citations
20.
Malapelle, Umberto, Simona Vatrano, Stefania Russo, et al.. (2015). EGFR mutant allelic-specific imbalance assessment in routine samples of non-small cell lung cancer. Journal of Clinical Pathology. 68(9). 739–741. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mazen Nasrallah Breakdown of academic impact, for papers by Lea Lowenfeld Breakdown of academic impact, for papers by Jason Cham Breakdown of academic impact, for papers by Laura Boullerot Breakdown of academic impact, for papers by Jichang Han Breakdown of academic impact, for papers by Rony Kapoor Breakdown of academic impact, for papers by Carlos Linn Breakdown of academic impact, for papers by Francesco Sgambelluri Breakdown of academic impact, for papers by Gareth Rivalland Breakdown of academic impact, for papers by Sandra Vogt
Rankless by CCL
2026